Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News BioSig Technologies Inc BSGM

Healthcare Medical Devices

BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is... see more

Add To Watchlist

Recent & Breaking News (NDAQ:BSGM)

BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19

GlobeNewswire April 24, 2020

ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research

GlobeNewswire April 23, 2020

Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

GlobeNewswire April 21, 2020

BioSig Subsidiary ViralClear Submits Application for Vicromax(TM) Through FDA's Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials

GlobeNewswire April 21, 2020

BioSig Issues April 2020 Shareholder Update Letter

GlobeNewswire April 17, 2020

Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax(TM)

GlobeNewswire April 16, 2020

Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv

GlobeNewswire April 9, 2020

BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19

GlobeNewswire April 3, 2020

Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.

GlobeNewswire March 31, 2020

BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

GlobeNewswire March 25, 2020

Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board

GlobeNewswire March 10, 2020

BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic Neuromodulation

GlobeNewswire March 4, 2020

BioSig to Webcast its Presentation at the Cowen and Company's 40th Annual Health Care Conference

GlobeNewswire March 3, 2020

BioSig to Present at the Cowen & Co. 40th Annual Health Care

GlobeNewswire February 26, 2020

BioSig Announces Closing of Public Offering of Common Stock

GlobeNewswire February 25, 2020

BioSig Announces $10 Million Public Offering of Common Stock

GlobeNewswire February 21, 2020

BioSig Announces Proposed Public Offering of Common Stock

GlobeNewswire February 20, 2020

BioSig Completes 100th Patient Case with PURE EP(TM) System

GlobeNewswire February 19, 2020

BioSig to Present at the 25th Annual International AF Symposium

GlobeNewswire January 21, 2020

BioSig to Commence Patient Cases at Mayo Clinic

GlobeNewswire January 16, 2020